Impaired TIGIT expression on B cells drives circulating follicular helper T cell expansion in multiple sclerosis

Hiromitsu Asashima, Pierre-Paul Axisa, Thi Hong Giang Pham, Erin E. Longbrake, William E. Ruff, Nikhil Lele, Inessa Cohen, Khadir Raddassi, Tomokazu S. Sumida, and David A. Hafler

Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA.

B cell depletion in patients with relapsing-remitting multiple sclerosis (RRMS) markedly prevents new MRI-detected lesions and disease activity, suggesting the hypothesis that altered B cell function leads to the activation of T cells driving disease pathogenesis. Here, we performed comprehensive analyses of CD40 ligand– (CD40L−) and IL-21–stimulated memory B cells from patients with MS and healthy age-matched controls, modeling the help of follicular helper T cells (Tfh cells), and found a differential gene expression signature in multiple B cell pathways. Most striking was the impaired TIGIT expression on MS-derived B cells mediated by dysregulation of the transcription factor TCF4. Activated circulating Tfh cells (cTfh cells) expressed CD155, the ligand of TIGIT, and TIGIT on B cells revealed their capacity to suppress the proliferation of IL-17–producing cTfh cells via the TIGIT/CD155 axis. Finally, CCR6+ cTfh cells were significantly increased in patients with MS, and their frequency was inversely correlated with that of TIGN+ B cells. Together, these data suggest that the dysregulation of negative feedback loops between TIGN+ memory B cells and cTfh cells in MS drives the activated immune system in this disease.

Introduction

Relapsing-remitting multiple sclerosis (RRMS) is a genetically mediated autoimmune disease mediated by myelin-reactive T cells attacking the CNS (1–3) and is characterized by inflammatory lesions predominantly in the white matter. B cell depletion in patients with RRMS markedly prevents new MRI-detected lesions and disease activity (4), suggesting that altered B cell function leads to the activation of T cells driving disease pathogenesis. Moreover, changes in T cell populations after B cell depletion therapies suggest that the interplay between T cells and B cells is a key feature of the disease pathogenesis (5).

The rapid decrease in disease activity after anti-CD20 antibody treatment despite a lack of major changes in oligoclonality in the cerebrospinal fluid (CSF) implies that antibody-independent B cell functions such as cytokine production and/or the expression of costimulatory or coinhibitory receptors are related to disease pathogenesis (2, 6). Specifically, circulating B cells from patients with MS produce more proinflammatory (IL-6, TNF, GM-CSF) and fewer antiinflammatory (IL-10) cytokines (7), and induction of B cells that enhance IL-10 production have been thought to have potential for clinical application (8–10). Coinhibitory receptors expressed on T cells have a pivotal role in the maintenance of immune homeostasis, and altered expression and function have been linked to autoimmune diseases (11–15). In this regard, Xiao et al. demonstrated that mice lacking T cell immunoreceptor with Ig and ITIM domains (TIGIT) expression in B cells (TIGIT−/− mice) developed severe experimental autoimmune encephalomyelitis (EAE) (16), suggesting the importance of TIGIT on B cells in maintaining CNS tolerance. However, whether TIGIT expression on B cells affects T cell function in MS pathogenesis is not known.

Specific subsets of CD4+ Th cells, such as Th1 and Th17 cells, have been suggested to play a critical role in MS pathogenesis (17, 18). In addition, recent data indicate that circulating T follicular helper (cTfh) cells are correlated with the progression of MS disability, and single-cell RNA-Seq (scRNA-Seq) data from human samples and mouse models demonstrated a pathological function of Tfh cells in the disease (19–21). Tfh cells can support B cell differentiation through IL-21 and other cell-surface molecules, while B cells can regulate Thf functions apart from antibody production (22–24). In the context of these data, we hypothesized that alterations in B cell function could drive the increased activation state of cTfh cells, leading to a hyperactive immune system in patients with MS.

Here, we show that, in patients with MS, memory B cells stimulated in vitro with CD40 ligand (CD40L) and IL-21, modeling the help of Tfh cells, have unique gene expression profiles compared with age-matched, healthy donor–derived memory B cells. Among differentially expressed genes (DEGs), TIGIT expression on MS-derived memory B cells was substantially impaired. Our in vitro experiments demonstrated that TCF4 was a key transcription factor for TIGIT expression and that TCF4 expression was dysregulated in patients with MS. Activated cTfh cells expressed CD155, the ligand of TIGIT, and TIGIT on B cells regulated the proliferation of cTfh cells and IL-17 production, independent of IL-10 production. Finally, the proportion of TIGN+ B cells was inverse-
ly correlated with the frequency of CCR6+ cThc cells, which was markedly increased in patients with MS. These data suggest that the interaction between TIGIT on activated memory B cells and CD155 on activated Tfh cells is a negative feedback mechanism to suppress the proliferation of Tfh cells, independent of IL-10 production, and that this feedback mechanism is impaired by dysregulation of the CD40/TCF4/TIGIT axis in patients with MS.

Results

Decreased TIGIT induction in MS-derived memory B cells after CD40L and IL-21 stimulation. We first compared in vitro–stimulated B cells between patients with MS and control individuals by examining mRNA expression levels. Since memory B cells comprise the majority of B cells in CSF (25–27), we focused on conventional CD20+CD27+ memory B cells. Memory B cells have direct contact with T cells, particularly follicular helper T (Tfh) cells, where they become reactivated (28–30). To model the help of Tfh cells in vitro, CD20+CD27+ MS patient–derived memory B cells (n = 8 patients) and control donor–derived memory B cells (n = 9 donors) were stimulated with CD40L and IL-21, and gene expression was evaluated by bulk RNA-Seq analysis. We identified 178 DEGs (∣log₂ fold change [FC]∣ > 0.5, FDR < 0.1) between MS patient– and healthy control–derived memory B cells based on their gene expression profiles (Figure 1A). Compared with the healthy control–derived memory B cells, 84 genes were significantly upregulated and 94 genes were downregulated in memory B cells from patients with MS (Figure 1B). Ingenuity Pathway Analysis (IPA) showed that the difference in gene expression between MS patient and healthy control cells was related to cell/cell signaling pathways (Figure 1C). The expression levels of molecules including LAIR1, SIT1, and ITGAV, which are related to cell–cell interactions, were validated by quantitative PCR (qPCR) (Figure 1D). These data suggest that the activated signatures of memory B cells induced by CD40 and IL-21 signaling were different between patients with MS and healthy control individuals.

Given the important role of TIGIT expression on B cells in maintaining CNS tolerance in murine models (31), we focused on the significant downregulation of TIGIT on MS patient–derived memory B cells (log₂ FC = −0.54, FDR = 0.01). We validated the decrease in expression of TIGIT by qPCR and flow cytometry (Figure 1, E and F). As PVR (also known as CD155) and NEC-TIN2 (also known as CD112) both bind the coinhibitory receptor TIGIT and the activating receptor CD226 (also known as DNAM-1) (14), we examined the expression of CD226 on B cells and found no difference between patients with MS and healthy controls (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI156254DS1). Moreover, no correlations were detected between the proportion of TIGIT+ B cells and demographic variables such as sex and age or disease activity and disease duration (Supplemental Figure 1, B–E). Thus, TIGIT expression on activated memory B cells was significantly downregulated in patients with MS, irrespective of background. The impaired signature in patients with MS, together with the regulatory role of TIGIT on B cells in a murine model of disease, suggests that the induction of TIGIT conferred the immunosuppressive signature on B cells.

TIGIT+ B cells are distinct from IL-10–producing B cells. Given that TIGIT contributes to IL-10 production in T cells (14, 32, 33) and TIGIT+ human B cells express more IL-10 after CpG (TLR9) stimulation (34), we reasoned that TIGIT expression could be overlapped with IL-10 production on human B cells after CD40L and IL-21 stimulation. To our surprise, the TIGIT+ cell population was highly distinct from the IL-10+ population, and the frequencies of TIGIT+IL-10+ B cells were negligible (Figure 2, A and B). To better understand the differences between TIGIT+ B cells and IL-10–producing B cells, we analyzed gene expression patterns using RNA-Seq (Figure 2C). Principal component analysis (PCA) placed TIGIT+IL-10+ (TIGIT+) B cells, TIGIT+IL-10− (IL-10+) B cells, and TIGIT+IL-10− (double-negative [DN]) B cells as distinctive cell populations, underlying their unique gene profile (Figure 2D). Of particular interest, the patterns of trafficking molecules, cytokines, and chemokines expressed by TIGIT+ B cells were distinct from those of IL-10+ B cells and DN B cells (Figure 2E). Moreover, PDCD1 (also known as PD-1) and CD226, but not BTLA or NTSE (also known as CD73), mRNAs were highly expressed in TIGIT+ B cells (Figure 2E). Although not all TIGIT+ B cells coexpressed PD-1 or CD226, flow cytometric analysis showed higher expression levels of these molecules in TIGIT+ B cells than in TIGIT− B cells (Figure 2F). HAVCR2 (also known as TIM3) also had a trend toward higher expression in TIGIT+ B cells (log₂ FC = 0.30, FDR = 0.14, compared with DN cells), whereas HAVCR1 (also known as TIM1) was not detected on B cells, diverging from observations in mice (16). TIGIT+ B cells expressed higher IL2RA (also known as CD25) but lower CD69 and FCER2 (also known as CD23) mRNA levels, indicating that TIGIT+ B cells were not simply in a more activated state than the other cell subsets (Figure 2E). Intriguingly, TIGIT+ B cells also produced more FGL2 than did TIGIT− B cells, which are known immunosuppressive molecules in Tregs (33) (Figure 2G). In total, these data suggest that the TIGIT+ B cells were not related to the IL-10–producing B cells and had a distinct pattern of gene expression.

Suppressed TIGIT expression in MS is unrelated to plasmablast differentiation program. We examined the expression of TIGIT and IL-10 in B cells following stimulation with CD40L and IL-21. As previously reported (35), CD27−CD38− plasmablasts had a higher capacity to express IL-10 (Supplemental Figure 2, A and B). On the other hand, TIGIT+ B cells expressed little CD38 after stimulation, which suggests that TIGIT expression was transient and disappeared after the differentiation of plasmablasts. There were no differences between the proportions of these B cell subsets when comparing cells from patients with MS and healthy controls (21, 36) (Supplemental Figure 2C), and, similarly, no differences were observed in the expression levels of the transcription factors IRF4, PRDM1, and XBP1 with regard to the plasmablast developmental program (37, 38) (Supplemental Figure 2D). Thus, the differentiation of plasmablasts suppressed TIGIT expression on B cells, and this signature was unrelated to the downregulation of TIGIT expression on MS–derived B cells.

Memory B cells have a unique capacity to express TIGIT. TIGIT expression on the surface membrane was negligible on human B cells, and there were no significant differences in the absolute numbers of ex vivo TIGIT+ B cells between healthy controls and
Figure 1. TIGIT is downregulated on memory B cells in MS. (A–C) Sorted CD20\(^+\)CD27\(^+\) memory B cells from patients with MS (n = 8) and healthy donors (HD) (n = 9) were cultured with CD40L and IL-21 for 2 days, and RNA-Seq was performed. (A) Heatmap of DEGs (|log\(_2\) FC| > 0.5, FDR < 0.1) in patients with MS and healthy donors. (B) Volcano plot depicting DEGs in memory B cells. Red dots represent significantly upregulated genes in MS-derived memory B cells, and blue dots represent significantly downregulated genes. Genes whose location is categorized as “plasma membrane” by IPA software are labeled. (C) IPA was performed to identify signatures related to altered molecular and cellular functions. Functions whose –log (Benjamini–Hochberg [B-H] P-value) values were greater than 1.8 are shown. (D–F) Sorted CD20\(^+\)CD27\(^+\) memory B cells from patients with MS and healthy donors (n = 12 each) were cultured with CD40L and IL-21 for 2 days. Gene expression was measured relative to B2M by qPCR (D and E). Representative flow data for TIGIT expression (F, left) and proportion of TIGIT\(^+\) cells (F, right). mB, memory B cells. Data are presented as the mean ± SEM and were evaluated by 2-tailed, unpaired Student’s t test (D–F). FSC-W, forward scatter width.
We further investigated which B cell subsets can express TIGIT after activation. We sorted B cells into 4 subsets according to CD27 and IgD expression levels and stimulated them with CD40L and IL-21 (Supplemental Figure 4, A and B). Compared with IL-10, which is produced by cells from all the subsets, CD19+CD20+CD27–IgD+ naive B cells did not express TIGIT, patients with MS (Supplemental Figure 3, A and B). Using our scRNA-Seq data sets (25), we also evaluated TIGIT expression on ex vivo B cells at the transcriptional level, and we found no differences between the 2 groups (Supplemental Figure 3, C–E). These data suggest that TIGIT expression is induced only after the activation of human B cells.

Figure 2. TIGIT is clearly separated from IL-10 expression. (A) Representative flow data of TIGIT and IL-10 expression in CD40L+IL-21–stimulated memory B cells. (B) The proportions of TIGIT+IL-10−, TIGIT+IL-10+, and TIGIT−IL-10+ (n = 23) cells were evaluated by 2-way ANOVA with Dunn’s multiple-comparison test. Data are presented as the mean ± SEM. (C) Experimental workflow for RNA-Seq with DN (TIGIT−IL-10−), TIGIT+IL-10−, and IL-10 (TIGIT−IL-10+) cells. (D) PCA of RNA-Seq transcriptomes (n = 3 healthy donors). (E) Heatmap of representative genes that were differentially expressed (log2FC > 0.5, FDR < 0.1) among 3 groups. (F) Representative flow data for PD-1 and CD226 (left) and their frequencies among TIGIT+ and TIGIT− cells (right). (G) Representative flow data for FGL2 (left) and its frequency among TIGIT+ and TIGIT− cells (right). Data are presented as the mean ± SEM. Significance was determined by 2-tailed, unpaired Student’s t test (F and G).
TCF4 is a key transcription factor for TIGIT expression on B cells.

To uncover the mechanism of TIGIT expression on B cells, we studied key transcription factors related to TIGIT regulation (Figure 4A). We identified 73 genes that were significantly upregulated in TIGIT+ B cells compared with IL-10+B cells and DN (TIGIT–IL-10–) B cells. Ten genes were categorized as transcription factors, and among them, we focused on TCF4 (also known as E2-2), as IL-4 treatment significantly downregulated its expression in concordance with TIGIT and resulted in high TCF4 expression levels in TIGIT+B cells (Figure 4, B and C). We examined the kinetics of TCF4 gene expression by qPCR and found that its expression was suppressed by IL-4 treatment from the early (4-hour) time point. In light of the TIGIT expression kinetics with later induction, the temporal change in TCF4 levels could explain its role as an upstream regulator of TIGIT (48–96 hours) (Figure 4D).

To clarify the relationship between TCF4 and TIGIT, we treated primary memory B cells with an siRNA targeting TCF4 and evaluated TIGIT expression (Figure 4, E and F). We achieved an approximately 50% knockdown of TCF4 gene expression (Figure 4E), and this significantly downregulated the expression of TIGIT (Figure 4, F and G). Moreover, we evaluated these signatures using Farage cells, a human B cell line (39) that expresses TIGIT ex vivo (Supplemental Figure 5A). TIGIT expression was upregul-
ed when cells were stimulated with CD40L, while IL-4 treatment suppressed TIGIT expression (Supplemental Figure 5, B–E). These data suggest that Farage cells have the same regulatory mechanisms of TIGIT expression as primary B cells and are useful for our analyses. We found that TCF4 knockout using CRISPR/Cas9 systems suppressed TIGIT expression (Supplemental Figure 5, F and G). Overall, these data showed that TCF4, downstream of CD40 signaling, induced TIGIT expression on human B cells.

Figure 4. TCF4 induces TIGIT expression on memory B cells. (A) Venn diagrams showing the overlapped genes. Significantly upregulated genes (log, FC > 0.5, FDR < 0.1) in TIGIT+IL-10− cells compared with TIGIT IL-10− cells and TIGIT IL-10− cells were evaluated. Among the 73 overlapped genes, transcription factors are highlighted, and heatmaps are depicted on basis of the log, FC under the IL-4-stimulated condition. *FDR < 0.1, **FDR < 0.01, and ***FDR < 0.001. (B) TIGIT+ and TIGIT− cells were sorted from CD20+CD27+ memory B cells stimulated with CD40L+IL-21 for 2 days, and TCF4 mRNA expression was measured relative to β2M by qPCR (n = 6). Significance was determined by 2-tailed, unpaired Student’s t test. (C) Representative histogram of TCF4 expression by flow cytometric analysis of TIGIT+ cells, TIGIT− cells, and control (no staining). Max, maximum. (D) mRNA expression kinetics of TCF4 and TIGIT from 7 different time points (n = 7). Data are presented as the mean ± SEM. (E–G) CD20+CD27+ memory B cells were transfected with an siRNA targeting TCF4 (siTCF4) or the control (siCtrl). TCF4 expression was measured relative to β2M by qPCR, and 51% knockdown efficiency was confirmed (E). Representative flow data for TIGIT expression (F) and the proportion of TIGIT+ cells (G). Data are presented as the mean ± SEM and were evaluated by 2-tailed, unpaired Student’s t test (E and G).
The CD40/TCF4/TIGIT axis is dysregulated in memory B cells in patients with MS. Inhibitors of DNA binding and cell differentiation (ID) proteins heterodimerize with basic helix-loop-helix transcription factors such as TCF4 and negatively regulate activity (40–42). To further investigate the relationship between TCF4 and TIGIT expression levels, we treated memory B cells with an siRNA targeting both ID2 and ID3 and evaluated gene signatures (Figure 5, A–C). Downregulation of both ID2 and ID3 substantially upregulated TIGIT expression without changing TCF4 expression levels. These data support our results showing that TCF4 is important for TIGIT expression on memory B cells. Although we detected no difference in expression levels of ID2 and ID3 between patients with MS and healthy controls, TCF4 expression was significantly downregulated on MS-derived memory B cells (Figure 5, D and E). Thus, in total, we found that the CD40/TCF4/TIGIT axis on memory B cells was dysregulated in patients with MS.

TIGIT on B cells suppresses the proliferation of CCR6+ Tfh cells. CD40L, also known as CD154, is predominantly expressed on CD4+ T cells, and CD40–CD154 interactions facilitate T cell–dependent B cell activation (43, 44). The importance of CD40 signaling for TIGIT expression on B cells led us to hypothesize that TIGIT ligation would drive T cell function. Thus, we evaluated the expression of the TIGIT ligands CD155 and CD112 on CD4+CD45RA+ memory T cells. Although both molecules were scarcely detectable on T cells ex vivo (data not shown), CD4+CD45RA CXCR5+ cTfh cells had significantly higher CD155 expression than did CD4+CD45RA CXCR5+ non-cTfh cells with anti-CD3/anti-CD28 stimulation (Figure 6, A and B). Furthermore, we observed that CD4+CD45RA CXCR5+CD127–CD25+ effector cTfh cells expressed higher levels of CD155 as compared with CD4+CD45RA CXCR5+CD127hiCD25hi regulatory Tfh cells (Supplemental Figure 6, A and B). There were no differences in CD112 expression between the 2 subsets of T cells (Figure 6C). CD155 expression on T cells mediates costimulatory TIGIT signaling, inducing tolerance and the subsequent suppression of cytokine production (45, 46). To evaluate whether TIGIT expression on activated B cells affected the proliferation of cTfh cells through the TIGIT/CD155 axis, we cocultured memory B cells and cTfh cells with anti-TIGIT antibody (34). TIGIT is also detected in T cells, and to clarify the function of TIGIT on B cells, memory B cells were stimulated with CD40L and IL-21 in combination with anti-TIGIT antibody or an isotype control, washed, and cocultured with CXCR5+ cTfh cells (Figure 6D). Intriguingly, we found that TIGIT expression on B cells suppressed the proliferation of cTfh cells (Figure 6, E and F). Moreover, IL-17 production from T cells significantly increased when TIGIT expression was blocked, and the supernatant from coculture assays also showed increased IL-17 secretion (Figure 6G and Supplemental Figure 7, A and B). To further evaluate the direct function of TIGIT on B cells, we cocultured CXCR5+ cTfh cells with B cells in which the TIGIT gene was deleted by an siRNA and observed the same trend (Supplemental Figure 7, C–E). These data suggest that memory B cells suppress the proliferation of cTfh cells, especially IL-17–producing cTfh cells, through the interaction between TIGIT on B cells and CD155 on cTfh cells.
increased in patients with MS (Figure 6I). These findings support our hypothesis that TIGIT+ B cells could suppress the proliferation of predominantly CCR6+ cTfh cells and that impairment of TIGIT expression on B cells alters the distribution of cTfh cells in patients with MS (Supplemental Figure 8).

Finally, we investigated the relationship between TIGIT+ B cells and CCR6+ cTfh cells, known as IL-17–producing cTfh cells (47). We found that the proportion of TIGIT+ B cells was inversely correlated with the proportion of CCR6+ cTfh cells (Figure 6H). Moreover, the proportion of CCR6+ cTfh cells significantly
Discussion

T-B cell interactions play a central role in adaptive immune responses and are highly relevant to autoimmune disease pathophysiology. Here, we performed comprehensive analyses of B cells from healthy age-matched controls compared with MS patient-derived memory B cells after stimulation with CD40L and IL-21 in vitro and found a differential gene signature in multiple B cell pathways. Most striking was the impaired TIGIT expression on MS patient–derived B cells mediated by dysregulation of the transcription factor TCF4. Our assessment of TIGIT+ B cells revealed their capacity to suppress the proliferation of IL-17-producing cTfh cells. Additionally, we found an inverse correlation between the frequency of TIGIT+ B cells and that of CCR6+ cTfh cells, which was increased in patients with MS. Together, these data suggest that the dysregulation of negative feedback loops between TIGIT+ memory B cells and cTfh cells in MS is one of the drivers of immune system activation in this disease (Supplemental Figure 8).

As screening of gene expression profiles of blood B cells ex vivo between patients with MS and controls from our scRNA-Seq data sets did not reveal differences (25), we hypothesized that perturbing the system in vitro rather than investigating the ex vivo steady state was necessary to better model the in vivo system. We found that memory B cells stimulated with CD40L and IL-21, modeling the help of Th cells, could allow us to distinguish between patients and controls. It was of interest that TIGIT expression was substantially downregulated after stimulation on memory B cells derived from patients with MS and that TIGIT-expressing B cells were IL-10+. While recent studies showed that TIGIT+ B cells produced more IL-10 after CpG stimulation (34), we found that TIGIT+ B cells and IL-10+ B cells clustered separately by PCA with RNA-Seq analysis. Moreover, as shown in Supplemental Figure 2A, although CD38+ plasmablasts have a higher capacity to express IL-10, TIGIT+ B cells expressed little CD38, which suggests that TIGIT expression disappears after B cells are differentiated into CD38+ plasmablasts.

Our RNA-Seq data revealed a unique gene profile of TIGIT+ B cells. Among coinhibitory receptors, programmed cell death 1 (PD-1) was found to be expressed on TIGIT+ B cells and had the same behavior as TIGIT expression under IL-4 stimulation. Intriguingly, PD-1+ B cells also possess a regulatory capacity toward a T cell response via the PD-1/PD-L1 pathway (48). Moreover, TIGIT+ B cells produced more fibrinogen-like 2 (FGL2), which has the capacity to suppress T cell proliferation (33, 49). While we demonstrated the regulatory function of TIGIT+ B cells on cTfh cells via TIGIT/CD155 pathways, TIGIT+ B cells might have additional regulatory functions through various signals.

We examined the transcriptional regulation of TIGIT and observed a role for TCF4 in regulating TIGIT expression in B cells, which were downregulated in patients with MS. This is of interest, as there are elevated levels of phosphorylated NF-κB after CD40 stimulation in MS-derived B cells (50), and the CD40 risk variant is related to the lower expression of CD40, affecting impaired B cell functions (1, 51, 52). Moreover, CD40 signaling in B cells is affected not only by genetic factors, but also by vitamin D3 levels, one of the environmental risk factors in MS. Although further investigation is needed, these observations suggest that the dysregulation of CD40 signaling is one of the critical signatures in MS-derived B cells linked to TIGIT expression.

We demonstrated that TIGIT expression on B cells could significantly suppress the proliferation of cTfh cells and IL-17 production in vitro. Moreover, the proportion of CCR6+ cTfh cells was markedly increased in the circulation of patients with MS. Consistent with our data, TIGIT-/- mice showed not only the development of more severe EAE, but also an increase in activated CD4+ T cells and IL-17 production (16). Furthermore, multimodal single-cell profiling of blood and spatial transcriptomes of brain tissues demonstrated Th17-like Tfh cells in the brains of patients with progressive MS (53). Together with the inverse correlation between TIGIT+ B cells and CCR6+ cTfh cells, we found that the impaired expression of TIGIT on activated B cells drove the expansion of Th17-like cTfh cells, suggesting a dysregulated loop leading to continued immune activation in patients with MS.

Although we performed a bidirectional analysis of T cells and B cells, we could not evaluate the direct interaction between TIGIT+ B cells and Th cells in the lymphoid tissue. The activation of Th cells is known to be critical for the reactivation of memory B cells, and intraval 2-photon microscopy has shown a direct contact not only at the T-B cell border but also at subcapsular proliferative foci (43, 54, 55). These proliferative foci represent a large surface that extends along the floor of the subcapsular sinus and predominantly consists of B cells, Th cells, and CD169+ macrophages. Intriguingly, migration into the subcapsular sinus intrinsically requires SIPR1 expression, which is characteristic of TIGIT+ B cells (Figure 2E), and scRNA-Seq analysis of mouse lymph nodes showed TIGIT expression on subcapsular proliferative foci–residing B cells (55). Moreover CCR6, one of the characteristic surface markers of IL-17–producing cTfh cells, is important for the accumulation of these cells near the subcapsular proliferative foci (56). Future studies are needed to elucidate the precise relationships between memory B cells and cTfh cells in human lymph nodes by spatial transcriptomics such as DBIT-Seq (57).

In summary, our data implicate a negative feedback loop between memory B cells and CCR6+ cTfh cells via TIGIT-CD155 interactions. These investigations provide a potential framework for assessing how immune responses converge after activation and how their dysregulation leads to the development of autoimmune diseases. Moreover, these data shed light on the coinhibitory receptors on B cells and provide potential insights into the antibody-independent functions of B cells in immune-mediated diseases with a possible contribution of aberrant T-B cell interactions.

Methods

Study participants

Peripheral blood was drawn from healthy individuals and patients with MS after informed consent was provided. The patients were diagnosed with RRMS according to the 2010 McDonald Criteria and had not been treated with any immunomodulatory therapies in the preceding 3 months at the time of the blood draw. The characteristics of the patients with MS in this study are listed in Supplemental Tables 1 and 2.

Human B and T cell isolation

PBMCs were isolated from donors by Lymphoprep (STEMCELL Technologies) gradient centrifugation. Total CD19+ B cells were isolated by negative magnetic selection using a Human B Cell Isolation
Kit (STEMCELL Technologies). In the B and T cell coculture experiments, CD3+ cells were first isolated using the Release Human CD3 Positive Selection Kit (STEMCELL Technologies).

Flow cytometry and cell sorting
For surface staining, single-cell suspensions were prepared from PBMCs and stained with fixable viability dye for 10 minutes at room temperature, followed by staining with surface antibodies for 30 minutes at 4°C. To measure absolute cell numbers, CountBright Absolute Counting Beads (Thermo Fisher Scientific) were used. For cytokine staining, GolgiStop (BD Biosciences) was added for the last 6 hours to B cells, and T cells were stimulated with PMA (50 ng/mL) and ionomycin (1,000 ng/mL) in the presence of GolgiStop (BD Biosciences) for 6 hours. Cells were fixed and permeabilized with the Cytofix/CytoPerm intracellular staining kit (BD Biosciences) for 30°C, followed by staining for 30 minutes at 4°C. For FGL2 staining, the rabbit monoclonal antibody (catalog PA5-71472; Invitrogen, Thermo Fisher Scientific) was prepared with the conjugation of the Zenon Rabbit IgG Labeling Kit (Thermo Fisher Scientific). For the staining of TCF4, cells were fixed and permeabilized with the Foxp3 Fix/Perm buffer set (eBioscience) for 45°C, followed by staining with TCF4 rabbit monoclonal antibody (catalog ab217668, NCI-R-159-6; Abcam) or an equivalent amount of normal rabbit IgG as a negative control (catalog ab172730, EPR252a; abcam) for 45 minutes at 4°C. After incubation with the primary antibodies, cells were washed and incubated for 30 minutes at 4°C with anti-rabbit IgG (catalog 406421, Poly4064; BioLegend) as a secondary antibody. Stained samples were analyzed with an LSR Fortessa flow cytometer (BD Biosciences). Data were analyzed with FlowJo software (Tree Star, version 10.4.2). The following antibodies and their clones were used: anti-CD2 (catalog 300222, RPA2.10), anti-CD4 (catalog 317410/317444, OKT4), anti-CD14 (catalog 325604, HCD14), anti-CD19 (catalog 302234/302256, HIB19), anti-CD20 (catalog 302340, 2H7), anti-CD27 (catalog 356418, M-T271), anti-CD38 (catalog 303504, HIT2), anti-CD56 (catalog 304604, MEM-188), anti-IL-10 (catalog 501404, JES-9D7), anti-CD112 (catalog 337114, TX31), anti-CD115 (catalog 337610/337614, SKIL4), anti-IFN-γ (catalog 506504, B27), anti-IL-17A (catalog 512322, BL168), anti-CD2 (catalog 329906, EH12.2H7), and anti-CD226 (catalog 338304, 11A8) (all from BioLegend); anti-CD2 (catalog 300222, RPA2.10), anti-CD4 (catalog 317410/317444, OKT4), anti-CD14 (catalog 325604, HCD14), anti-CD19 (catalog 302234/302256, HIB19), anti-CD20 (catalog 302340, 2H7), anti-CD27 (catalog 356418, M-T271), anti-CD38 (catalog 303504, HIT2), anti-CD56 (catalog 304604, MEM-188), anti-IL-10 (catalog 501404, JES-9D7), anti-CD112 (catalog 337114, TX31), anti-CD115 (catalog 337610/337614, SKIL4), anti-IFN-γ (catalog 506504, B27), anti-IL-17A (catalog 512322, BL168), anti-CD2 (catalog 329906, EH12.2H7), and anti-CD226 (catalog 338304, 11A8) (all from BioLegend); anti-CD2 (catalog 300222, RPA2.10), anti-CD4 (catalog 317410/317444, OKT4), anti-CD14 (catalog 325604, HCD14), anti-CD19 (catalog 302234/302256, HIB19), anti-CD20 (catalog 302340, 2H7), anti-CD27 (catalog 356418, M-T271), anti-CD38 (catalog 303504, HIT2), anti-CD56 (catalog 304604, MEM-188), anti-IL-10 (catalog 501404, JES-9D7), anti-CD112 (catalog 337114, TX31), anti-CD115 (catalog 337610/337614, SKIL4), anti-IFN-γ (catalog 506504, B27), anti-IL-17A (catalog 512322, BL168), anti-CD2 (catalog 329906, EH12.2H7), and anti-CD226 (catalog 338304, 11A8) (all from BioLegend); anti-CD2 (catalog 300222, RPA2.10), anti-CD4 (catalog 317410/317444, OKT4), anti-CD14 (catalog 325604, HCD14), anti-CD19 (catalog 302234/302256, HIB19), anti-CD20 (catalog 302340, 2H7), anti-CD27 (catalog 356418, M-T271), anti-CD38 (catalog 303504, HIT2), anti-CD56 (catalog 304604, MEM-188), anti-IL-10 (catalog 501404, JES-9D7), anti-CD112 (catalog 337114, TX31), anti-CD115 (catalog 337610/337614, SKIL4), anti-IFN-γ (catalog 506504, B27), anti-IL-17A (catalog 512322, BL168), anti-CD2 (catalog 329906, EH12.2H7), and anti-CD226 (catalog 338304, 11A8) (all from BioLegend); anti-CD3 (catalog 555332, UCHT1), anti-CD45RA (catalog 560674, H1010), anti-CCXCR5 (catalog 558113, RF8B2), anti-CD25 (catalog 356418, M-A251), and anti-CD127 (catalog 560549, HIL-7R-M21) (all from BD Biosciences); and anti-TIGIT (catalog 51-9500-42, MBSA43) (eBioScience).

Cell culture
B cells. After the isolation of CD19+ B cells from PBMCs using the Human B cell Isolation Kit as described above, CD20+CD27−/−IGD−/− B cells were sorted on a FACSAria (BD Biosciences) and stimulated with CD40L (0.1 μg/mL) (Enzo) and IL-21 (20 ng/mL) (R&D Systems) for 2 days in RPMI 1640 medium (Gibco, Thermo Fisher Scientific) supplemented with 10% FBS, 2 mM l-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin (Lonza) using 96-well round-bottomed plates. (Corning).

T cells. After the isolation of CD3+ T cells from PBMCs using the Human T cell Isolation Kit as above, CD4+CD45RA CCXCR5+/− T cells were sorted and cultured in the above media. Ninety-six-well round-bot-
Human TCF4 (6925) siRNA, ON-TARGETplus Human ID2 (3398) siRNA, ON-TARGETplus Human ID3 siRNA (3399), ON-TARGETplus Human XBP1 (7494) siRNA, ON-TARGETplus Human TIGIT (201633) siRNA, and ON-TARGETplus Non-targeting Pool (control).

CRISPR gene knockout
Assembly of ribonucleoproteins (RNPs) was performed as previously described (58). Briefly, chemically synthesized CRISPR-targeting RNA (crRNA) (Dharmacon) and trans-activating crRNA (tracrRNA) (Dharmacon) at concentrations of 160 μM were mixed and incubated at 37°C for 30 minutes to form guide RNA (gRNA) at a concentration of 80 μM. This gRNA was mixed at a 1:1 ratio by volume with 40 μM Strepotagged pgoygenes Cas9 (UC Berkeley QB3 MacroLab) and incubated at 37°C for 15 minutes to form RNPs at a concentration of 20 μM. Farage cells (American Type Culture Collection [ATCC]; CRL-2630) were pooled and centrifuged at 200g for 8 minutes at room temperature. The supernatant was removed and the cell pellets were resuspended in SG 4D-Nucleofector X solution (Lonza). The final concentration of cells used for nucleasection was 4 × 10⁶ cells/20 μL. Cells were nucleasectioned with 4 μL RNPs using the program “CA-137” for B cell lines of the Amaza 4D Nucleofector system (Lonza). Immediately after nucleasection, 80 μL prewarmed culture media (same as above) were added to the cuvette, and cells were rested in the incubator for 30 minutes at 37°C. After resting, 20 μL was transferred from the cuvette into 96-well round-bottomed wells with 180 μL prewarmed culture media, and a total of 5 wells (0.8 × 10⁶ cells/200 μL) per RNP were set. Cells were cultured for 2 days, and further analyses were performed. The adopted crRNAs (Dharmacon) were as follows: Edit-R Human Synthetic TCF4 (6925) sgRNA and Edit-R Modified Synthetic crRNA (Scramble; 5’-GGTTCTTGACTACCGTAAT-3’).

RNA-Seq
Preparation of cells. For the analysis of differences between B cells derived from patients with MS and B cells from healthy donors, CD19+ B cells were isolated from PBMCs using the Human B Cell Isolation Kit, and CD20+CD27- memory B cells were harvested after the stimulation with CD40L (0.1 μg/mL) plus IL-21 (20 ng/mL) for 2 days. Samples were collected from 8 patients from RRMS and 9 healthy donors. For the analysis of TIGIT expression on B cells, CD3 CD14- CD56-CD20+CD27+ memory B cells were sorted and stimulated with CD40L (0.1 μg/mL) plus IL-21 (20 ng/mL). After 2 days, TIGIT IL-10- B cells, TIGIT+IL-10- B cells, and TIGIT+IL-10+ B cells were sorted using an IL-10 detection assay (Miltenyi Biotech). CD20+CD27+ memory B cells were also stimulated with CD40L (0.1 μg/mL) or CD40L (0.1 μg/mL) plus IL-4 (10 ng/mL) for 2 days and harvested. Samples were collected from 3 healthy donors.

cDNA and library preparation and sequencing. RNA was isolated using the RNeasy Plus Micro Kit (QIAGEN), and cDNAs were generated using the SMART-Seq, version 4, Ultra Low Input RNA Kit for sequencing (Takara/Clontech). Barcoded libraries were generated using the Nextera XT DNA Library Preparation kit (Illumina) and sequenced with a 2 × 100 bp paired-end protocol on the HiSeq 4000 or NovaSeq 6000 Sequencing System (Illumina).

RNA-Seq data analysis. Low-quality ends (Phred score <30) and short read length (minimum length = 30) was trimmed using PRINSEQ++ (version 1.2) (59). Trimmed reads were aligned to the hg38 genome reference using STAR (version 2.7.1) (60), and subse-

quently, RSEM (61) was used to count reads mapping to the genes from Ensembl release 93. For the removal of unwanted variation, the top 5000 genes ranked by edgeR (62) P values were set as “in silico empirical” negative controls, and RUVSeq (Biocductor) (63) was performed. Pair-wise differential expression was analyzed using the R package Deseq2 (64). The cutoff value to select DEGs is provided in each figure legend. Significantly upregulated and downregulated genes from RNA-Seq analyses are shown in Supplemental Table 3.

Data availability. RNA-Seq data were deposited in the NCBI’s Gene Expression Omnibus (GEO) database (GEO GSE21135).

scRNA-Seq
A PBMC scRNA-Seq data set that we had previously generated (25) was reanalyzed. Gene-cell matrices were analyzed using the Seurat (65, 66) package in R (version 3.6.2), including data integration, clustering, multiplet identification, and cell type annotation. The top 2000 variable genes were selected, and integration anchors were determined by “FindIntegrationAnchors.” These anchors were used to integrate the data using the “IntegrateData” function with the top 30 dimensions and scaled. The top 10 principal components (PCs) were used for data integration and downstream steps, along with a clustering resolution of 0.7. Cluster-specific gene expression profiles were established using the “FindAllMarkers” per cluster and per subset to annotate the clusters. Doublet clusters were determined by coexpression of heterogeneous lineage markers (e.g., MS4A1 and CD3), and these clusters were removed prior to finalizing the UMAPs.

Statistics
All statistical analyses were performed using GraphPad Prism 7 (GraphPad Software). Detailed information about statistical analysis, including tests and values, is provided in the figure legends. P values of less than 0.05 were considered significant.

Study approval
This study was approved by the IRB of Yale University (2000027291 REG). All experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. The study participants provided informed consent.

Author contributions
The experiments were conceptualized by HA, TSS, and DAH. HA performed the experiments, analyzed data, and wrote the original draft. PPA, THGP, NL, WER, IC, KR, and EEL helped with sample collection, experiments, and data analyses. TSS and DAH supervised the experiments. All authors reviewed the manuscript.

Acknowledgments
We thank L. Devine and C. Wang for cell sorting; M. Zhang for preparation of the RNA-Seq libraries; G. Wang and C. Castaldi at the Yale Center for Genome Analysis for support with 10X Genomics library preparation and sequencing; P. Coish for his proof reading (all from Yale University); Y. Yamashita-Kanemaru (University of Cambridge) and H. Miki (La Jolla Institute of Immunology) for useful discussions; and M. Comi (Yale University) for helpful feedback on the manuscript. HA
thanks the Daiichi Sankyo Foundation of Life Science and the Uehara Memorial Foundation for his fellowship. This study was supported by grants to DAH from the NIH (U19 AI089992, R25 NS071913, P01 AI073748, U24 AI11867, R01 AI22220, UM 1HG009390, P01 AI039671, P50 CA121974, and R01 CA227473); the National Multiple Sclerosis Society (NMSS) (CA 1061- A-18 and RG-1802-30153); the Nancy Taylor Foundation for Chronic Diseases; and Erase MS. EEL received grants from the NIH (K23 107624) and a Clinical and Translational Science Award (CTSA) (KL2 TR001862) from the National Center for Advancing Translational Science (NCATS), NIH. RNA-Seq services were conducted at the Yale Center for Genome Analysis and the Yale Stem Cell Center Genomics Core facility, the latter being supported by the Connecticut Regenerative Medicine Research Fund and the Li Ka Shing Foundation.

Address correspondence to: David A. Hafler, Departments of Neurology and Immunobiology, Yale School of Medicine, 300 George Street, 3rd floor, New Haven, Connecticut 06511, USA. Phone: 203.737.4802; Email: david.hafler@yale.edu.

1. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):eaax7188.
2. Li R, et al. Reassessing B cell contributions in multiple sclerosis. Nat Immunol. 2018;19(7):696-707.
3. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122(4):1180-1188.
4. Hauser SL, et al. B-cell depletion with rituximab for relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688.
5. Lovett-Racke AE, et al. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol. 2019;332:187-197.
6. Coni G, et al. Role of B cells in multiple sclerosis and related disorders. Ann Neurol. 2021;90(1):13-23.
7. Li R, et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7(310):310ra166.
8. Muzzi A, Rosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221-241.
9. Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity. 2015;42(4):607-612.
10. Peng B, et al. Regulatory B cells: the cutting edge of immune tolerance in kidney transplantation. Cell Death Dis. 2018;9(2):109.
11. Oliveira EML, et al. CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls. J Autoimmun. 2003;20(1):71-81.
12. Maier LM, et al. Allelic variant in CTLA4 alters T cell susceptibility to viral infection. Proc Natl Acad Sci U S A. 2007;104(47):18607-18612.
13. Zhang Q, Vignali DAA. Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunology. 2016;144(5):1034-1051.
14. Anderson AC, et al. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989-1004.
15. Lucca LE, Dominguez-Villar M. Modulation of regulatory T cell function and stability by co-inhibitory receptors. Nat Rev Immunol. 2020;20(11):680-693.
16. Xiao S, et al. Checkpoint receptor TIGIT Expressed on Tim-1 B cells regulates tissue inflammation. Cell Rep. 2020;32(2):107892.
17. Cao Y, et al. Functional inflammatory profiles files distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci Transl Med. 2015;7(287):287ra74.
18. Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med. 2018;8(3):a028936.
19. Romme Christensen J, et al. Correction: systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One. 2013;8(3):10.1371/annotation/b4e623eb-4950-4b9d-89d8-8d04269d95a3.
20. Quinn JL, Axtell RC. Emerging role of follicular T helper cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Int J Mol Sci. 2018;19(10):3233.
21. Schafflick D, et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat Commun. 2020;11(1):247.
22. Ueno H. T follicular helper cells in human autoimmunity. Curr Opin Immunol. 2016;45:24-31.
23. Nas M, et al. Marginal zone B cells control the response of follicular helper T cells to a high-cholesterol diet. Nat Med. 2017;23(5):601-610.
24. Achour A, et al. Human regulatory B cells control the Treg cell response. J Allergy Clin Immunol. 2017;140(1):215–222.
25. Pappalardo JL, et al. Transcriptomic and clonal characterization of T cells in the human central nervous system. Sci Immunol. 2020;5(51):eabb8786.
26. Eggers EL, et al. Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. JCI Insight. 2017;2(22):92274.
27. Corcione A, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A. 2004;101(30):11064-11069.
28. Jelicic I, et al. Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell. 2018;175(1):85-100.
29. MacLeod MRL, et al. Memory CD4 T cells that express CXCR5 provide accelerated help to B cells. J Immunol. 2013;186(5):2889-2896.
30. Inoue T, et al. Generation of memory B cells and their reactivation. Immunol Rev. 2018;283(1):138-149.
31. Xiao S, et al. Tim-1 is essential for induction and maintenance of IL-10 in regulatory B cells and their regulation of tissue inflammation. J Immunol. 2015;194(4):1602-1608.
32. Burton BR, et al. Serial transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun. 2014;5:4741.
33. Joller N, et al. Treg cells expressing the co-inhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40(4):569-581.
34. Hasan MM, et al. Implication of TIGIT+ human membro B cells in immune regulation. Nat Commun. 2021;12(1):3314.
35. Matsumoto M, et al. Interleukin-10-producing plasmablasts exert regulatory function in autoimmunity and inflammation. Immunity. 2014;41(6):1040-1051.
36. Yilmaz V, et al. Flow cytometry analysis of peripheral blood B cell distribution of patients with multiple sclerosis. Turkish J Neurol. 2017;23(4):219-224.
37. Nutt SL, et al. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15(3):160–171.
38. Tellier J, et al. Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response. Nat Immunol. 2016;17(5):323–330.
39. Baruch M, et al. Molecular characterization of an unusual non-Hodgkin’s B-lymphoma cell line (“Farge”) lacking the ability to produce immunoglobulin polypeptide chains. Leuk Lymphoma. 1996;25(1):485-495.
40. Kee BL, E and ID proteins branch out. Nat Rev Immunol. 2009;9(3):175-184.
41. Murre C. Helix-loop-helix proteins and lymphocyte development. Nat Immunol. 2005;6(11):1079-1086.
42. Gloury R, et al. Dynamic changes in Ids and E-protein activity orchestrate germinal center and plasma cell development. J Exp Med. 2016;213(6):1095-1111.
43. Kurosaki T, et al. Memory B cells. Nat Rev Immunol. 2015;15(3):149–159.
44. Karnell JL, et al. Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv Drug Deliv Rev. 2019;141:92-103.
45. Yamashita-Kanemaru Y, et al. CD155 (PVR/Necl5) mediates a costimulatory signal in CD4+ T cells and regulates allergic inflammation. J Immunol. 2015;194(12):5644–5653.
46. Negishi N, et al. CD155 transducing signaling through TIGIT plays an important role in transmission of tolerant state and suppression capacity. Immunol Horizons. 2018;2(10):338-348.
47. Morita R, et al. Human blood CXCR5(+)/CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34(1):108-121.
48. Wang X, et al. PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway. Mol Immunol. 2019;109:20-26.
49. Sun Y, et al. Soluble FGL2, a novel effector molecule
of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma. *Hepatol Int*. 2014;8(4):567–575.
50. Chen D, et al. CD40-mediated NF-κB activation in B cells is increased in multiple sclerosis and modulated by therapeutics. *J Immunol*. 2016;197(11):4257–4265.
51. Field J, et al. The MS risk allele of CD40 is associated with reduced cell-membrane bound expression in antigen presenting cells: implications for gene function. *PLoS One*. 2015;10(6):e0127080.
52. Smets I, et al. Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. *Brain*. 2018;141 (5):786–796.
53. Kaufmann M, et al. Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. *Med (NY)*. 2021;2(3):296–312.
54. Ise W, et al. Memory B cells contribute to rapid Bcl6 expression by memory follicular helper T cells. *Proc Natl Acad Sci U S A*. 2014;111(32):11792–11797.
55. Moran I, et al. Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes. *Nat Commun*. 2018;9(1):3372.
56. Zhang Y, et al. Migratory and adhesive cues controlling innate-like lymphocyte surveillance of the pathogen-exposed surface of the lymph node. *Elife*. 2016;5:e18156.
57. Liu Y, et al. High-spatial-resolution multi-omics sequencing via deterministic barcoding in tissue. *Cell*. 2020;183(6):1665–1681.
58. Wu CAM, et al. Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins. *J Immunol Methods*. 2018;457:33–40.
59. Cantu VA, et al. PRINSEQ++, a multi-threaded tool for fast and efficient quality control and preprocessing of sequencing datasets [preprint]. https://doi.org/10.7287/peerj.preprints.27553v1. Posted on PeerJPreprints February 27, 2019.
60. Dobin A, et al. STAR: ultrafast universal RNA-Seq aligner. *Bioinformatics*. 2013;29(1):15–21.
61. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics*. 2011;12:323.
62. Robinson MD, et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*. 2010;26(1):139–140.
63. Risso D, et al. Normalization of RNA-seq data using factor analysis of control genes or samples. *Nat Biotechnol*. 2014;32(9):896–902.
64. Love MI, et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550.
65. Butler A, et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol*. 2018;36(5):411–420.
66. Stuart T, et al. Comprehensive integration of single-cell data. *Cell*. 2019;177(7):1888–1902.